MedTrace Logo

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

NCT00245648 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-10-04

No results posted yet for this study

Summary

This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.

Conditions

Interventions

DRUG

fibrinolytic therapy or combination reduced fibrinolytic therapy

Sponsors & Collaborators

Principal Investigators

  • Harmony Reynolds · NYU School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245648 on ClinicalTrials.gov